Acute Myeloid Leukemia Clinical Trial
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
Summary
The primary objective of this study is to evaluate the safety and tolerability of AMG 330, administered in combination with pembrolizumab, in participants with relapsed or refractory acute myeloid leukemia (R/R AML).
Full Description
This study will assess the safety and tolerability of AMG 330 in combination with pembrolizumab and whether pembrolizumab will enhance the anti-AML activity of AMG 330. Both cohort 1 and 2 will include AMG 330 and pembrolizumab with the difference being the initiation date for pembrolizumab treatment.
Eligibility Criteria
Key Inclusion criteria
AML as defined by the WHO Classification persisting or recurring following one or more treatment courses. Except APL
Eastern Cooperative Oncology Group (ECOG) ≤1
Key Exclusion criteria
Active extramedullary AML in the central nervous system.
Known hypersensitivity to immunoglobulins.
Non-manageable graft versus host disease.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Duarte California, 91010, United States
Houston Texas, 77030, United States
How clear is this clinincal trial information?